Nathan Vastesaeger

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
    Nathan Vastesaeger
    Department of Medical Affairs, MSD Danmark ApS, Ballerup, Denmark
    Rheumatology (Oxford) 55:1466-76. 2016
  2. doi request reprint ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy
    Nathan Vastesaeger
    Merck Sharp and Dohme, Brussels, Belgium Electronic address
    Reumatol Clin 10:204-9. 2014
  3. pmc Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
    Asta Baranauskaite
    Kaunas Medical University Hospital, Kaunas, Lithuania
    Ann Rheum Dis 71:541-8. 2012
  4. pmc Predicting the outcome of ankylosing spondylitis therapy
    Nathan Vastesaeger
    Schering Plough Corporation, Kenilworth, New Jersey, USA
    Ann Rheum Dis 70:973-81. 2011

Detail Information

Publications4

  1. pmc Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
    Nathan Vastesaeger
    Department of Medical Affairs, MSD Danmark ApS, Ballerup, Denmark
    Rheumatology (Oxford) 55:1466-76. 2016
    ..To create a tool to predict probability of remission and low disease activity (LDA) in patients with RA being considered for anti-TNF treatment in clinical practice...
  2. doi request reprint ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy
    Nathan Vastesaeger
    Merck Sharp and Dohme, Brussels, Belgium Electronic address
    Reumatol Clin 10:204-9. 2014
    ..To investigate which of the 2 ankylosing spondylitis (AS) disease activity instruments identifies better those patients with characteristics that have been associated with positive response to anti-TNF therapy...
  3. pmc Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
    Asta Baranauskaite
    Kaunas Medical University Hospital, Kaunas, Lithuania
    Ann Rheum Dis 71:541-8. 2012
    ..To compare the efficacy and safety of treatment with infliximab plus methotrexate with methotrexate alone in methotrexate-naive patients with active psoriatic arthritis (PsA)...
  4. pmc Predicting the outcome of ankylosing spondylitis therapy
    Nathan Vastesaeger
    Schering Plough Corporation, Kenilworth, New Jersey, USA
    Ann Rheum Dis 70:973-81. 2011
    ....